Engage Therapeutics

Summit, United States Founded: 2017 • Age: 9 yrs Acquired By UCB
Inhaled drug-device combo as rescue treatment for uncontrolled epileptic seizures
Request Access

About Engage Therapeutics

Engage Therapeutics is a company based in Summit (United States) founded in 2017 was acquired by UCB in June 2020.. Engage Therapeutics has raised $30.6 million across 2 funding rounds from investors including UCB, TPG and Adage Capital Management. Engage Therapeutics operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.

  • Headquarter Summit, United States
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $30.6 M (USD)

    in 2 rounds

  • Latest Funding Round
    $7 M (USD), Series A

    Oct 29, 2019

  • Investors
    UCB

    & 4 more

  • Employee Count
    Employee Count
  • Acquired by
    UCB

    (Jun 05, 2020)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Engage Therapeutics

Engage Therapeutics has successfully raised a total of $30.6M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $7 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series A — $7.0M
  • First Round

    (10 Oct 2017)

  • Investors Count 4
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2019 Amount Series A - Engage Therapeutics Valuation

investors

Oct, 2017 Amount Series A - Engage Therapeutics Valuation TPG , Adage Capital Management
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Engage Therapeutics

Engage Therapeutics has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include UCB, TPG and Adage Capital Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Fund of funds focused on pre-seed and seed-stage companies
Founded Year Domain Location
Healthcare startups are funded by this corporate-backed venture capital entity.
Founded Year Domain Location
Lumira Ventures is engaged in life sciences venture capital investment.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Engage Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Engage Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Engage Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Engage Therapeutics

Engage Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of pharmaceuticals and vaccines for various therapeutic areas
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Yeast cells are genetically engineered to produce medicinal products.
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
domain founded_year HQ Location
CRISPR-engineered cell and gene therapies are developed for research applications.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Engage Therapeutics

When was Engage Therapeutics founded?

Engage Therapeutics was founded in 2017.

Where is Engage Therapeutics located?

Engage Therapeutics is headquartered in Summit, United States.

Is Engage Therapeutics a funded company?

Engage Therapeutics is a funded company, having raised a total of $30.6M across 2 funding rounds to date. The company's 1st funding round was a Series A of $23.6M, raised on Oct 10, 2017.

What does Engage Therapeutics do?

Engage Therapeutics is a clinical-stage biopharma developing an inhaled drug-device combo as rescue treatment for uncontrolled epileptic seizures. The Staccato is a handheld inhaler that administers the drug alprazolam and is intended as a rescue treatment like an EpiPen. The Staccato alprazolam combo was shown in a phase 2a trial to halt seizure-like activity in two minutes. Engage Therapeutics licensed the tech from Alexza Pharmaceuticals.

Who are the top competitors of Engage Therapeutics?

Engage Therapeutics's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.

Who are Engage Therapeutics's investors?

Engage Therapeutics has 5 investors. Key investors include UCB, TPG, Adage Capital Management, LifeSci Venture Partners, and Lumira Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available